Last updated: September 21, 2026
Lomitapide mesylate is a niche, high-value treatment for homozygous familial hypercholesterolemia, or HoFH. Its commercial position is supported by severe disease, limited alternatives, and orphan-drug economics, but constrained by a small addressable population, hepatotoxicity monitoring, restricted distribution, reimbursement friction, and competition from evinacumab and LDL apheresis. The product was marketed as Juxtapid in the United States and Lojuxta in Europe. Chiesi acquired the product through its $1.25 billion acquisition of Amryt Pharma in 2023.[1]
What is lomitapide mesylate used for?
Lomitapide is an oral microsomal triglyceride transfer protein inhibitor. It reduces the assembly and secretion of apolipoprotein B-containing lipoproteins, including very-low-density lipoprotein and chylomicrons. The FDA approved Juxtapid in December 2012 as an adjunct to a low-fat diet and other lipid-lowering treatments for adults with HoFH.[2]
The product is not intended for routine hypercholesterolemia. Its commercial use is concentrated in patients with genetically confirmed or clinically diagnosed HoFH who remain at high risk despite statins, ezetimibe, PCSK9-directed therapy, and, in some cases, LDL apheresis.
| Attribute |
Lomitapide mesylate |
| U.S. brand |
Juxtapid |
| European brand |
Lojuxta |
| Active mechanism |
Microsomal triglyceride transfer protein inhibition |
| Primary disease |
Homozygous familial hypercholesterolemia |
| U.S. approval |
Dec. 21, 2012 |
| U.S. sponsor at launch |
Aegerion Pharmaceuticals |
| Current corporate owner |
Chiesi Farmaceutici, through Amryt Pharma |
| Dosage form |
Oral capsules |
| Key safety issue |
Hepatic steatosis and transaminase elevations |
| U.S. regulatory controls |
Risk Evaluation and Mitigation Strategy, or REMS |
How large is the lomitapide mesylate market?
The treated market is small in volume but large in value per patient. HoFH prevalence estimates commonly range from approximately one patient per 250,000 to one per 400,000 people, although genetic screening and improved diagnosis have expanded the identified population.[3]
The addressable market includes:
- Diagnosed adults with HoFH.
- Patients unable to achieve adequate LDL-C reduction with conventional treatment.
- Patients who cannot tolerate or do not adequately respond to LDL apheresis.
- Patients in countries where specialist lipid centers and reimbursement programs support access.
The commercial ceiling is limited by disease prevalence. A global population of several thousand treated HoFH patients can support a specialty product with a high annual treatment cost, but it cannot produce the scale of a PCSK9 inhibitor or a conventional statin.
Lomitapide also has a narrower label than newer therapies. Evinacumab, marketed as Evkeeza, received FDA approval in 2021 for adults and pediatric patients aged 12 years and older with HoFH. Its approval created a direct competitive alternative for the same high-risk population.[4]
What is the financial trajectory of lomitapide?
Lomitapide generated substantial revenue for Aegerion during the middle of the 2010s, but sales growth weakened as the company encountered pricing scrutiny, patient-access pressure, compliance issues, and a limited eligible population.
Aegerion’s financial trajectory followed four stages:
| Period |
Commercial development |
Financial implication |
| 2012-2014 |
FDA launch and rapid uptake in specialist HoFH centers |
Strong early revenue growth from a high annual treatment price |
| 2015-2017 |
Broader commercialization but increasing access and compliance pressure |
Revenue remained material but failed to support the original growth profile |
| 2017-2019 |
Corporate restructuring, debt pressure, and transition to Novelion and then Amryt |
Product retained strategic value despite sponsor instability |
| 2020-2023 |
Amryt expanded the rare-disease portfolio and was acquired by Chiesi |
Lomitapide became one asset within a diversified rare-disease platform |
| 2023 onward |
Chiesi ownership and private-company reporting |
Product-level revenue disclosure became limited |
Aegerion’s public filings reported Juxtapid as the company’s principal commercial product. The drug’s economics were favorable at the gross-margin level because it was an oral specialty medicine with manufacturing costs well below its selling price. Net revenue was reduced by payer rebates, patient assistance, distribution costs, returns, and treatment discontinuation.
The principal financial weakness was the fixed size of the patient population. Price increases could raise revenue per patient, but they also intensified payer restrictions and political scrutiny. High discontinuation rates or delayed diagnosis had a direct effect on sales because the product had few potential replacement patients outside the HoFH population.
Amryt did not generally disclose lomitapide revenue as a standalone line after its portfolio expanded. Chiesi is privately held and does not publish the same level of product-level financial detail as a public pharmaceutical company. The acquisition therefore reduced visibility into current lomitapide sales, margins, and patient counts.[1]
Who owns lomitapide mesylate?
Aegerion obtained rights to lomitapide from Bristol-Myers Squibb and developed the product for HoFH. Aegerion launched Juxtapid in the United States after FDA approval. Corporate ownership later moved through several transactions:
- Aegerion commercialized Juxtapid and built the initial U.S. franchise.
- Aegerion entered financial distress and underwent restructuring.
- Novelion Pharmaceuticals acquired Aegerion.
- The combined business was renamed Amryt Pharma.
- Chiesi agreed to acquire Amryt in 2023 for approximately $1.25 billion.[1]
Chiesi’s ownership provides a broader rare-disease commercial infrastructure and reduces the standalone-company risk that affected Aegerion. The transaction also means that lomitapide is no longer the financial center of an independent public company.
What are the main market dynamics affecting lomitapide?
High price and reimbursement constraints
Lomitapide was introduced at a high annual treatment cost consistent with orphan-drug pricing. The effective net price varies by country, payer, dose, assistance program, and duration of therapy.
Payers generally require:
- Confirmed HoFH diagnosis.
- Documentation of prior lipid-lowering treatment.
- Evidence of inadequate LDL-C control.
- Treatment through a specialist.
- Continued liver-function monitoring.
- Periodic reassessment of clinical response.
These requirements reduce immediate uptake but can improve persistence among patients who gain access.
Safety and monitoring burden
Lomitapide carries clinically important hepatic risks. The FDA label warns of hepatic steatosis, steatohepatitis, and progressive liver disease. Patients require baseline and periodic liver tests. The drug also has gastrointestinal adverse effects and meaningful drug-interaction restrictions.[2]
The safety burden affects revenue in two ways. It limits use in patients with liver disease and increases the administrative cost of prescribing. It also gives physicians a reason to consider evinacumab or apheresis when LDL-C reduction can be achieved without chronic hepatic exposure.
Small and concentrated prescriber base
Prescribing is concentrated in lipid specialists, endocrinologists, cardiologists, and a limited number of HoFH centers. This supports targeted commercialization and reduces the need for broad sales infrastructure. It also makes the product vulnerable to treatment-center protocols and national reimbursement decisions.
Competition from evinacumab
Evinacumab is the strongest branded competitive threat. It uses an angiopoietin-like 3, or ANGPTL3, antibody mechanism and reduces LDL-C through a pathway that does not depend on functional LDL receptors to the same extent as many conventional therapies.[4]
| Factor |
Lomitapide |
Evinacumab |
| Modality |
Oral small molecule |
Intravenous monoclonal antibody |
| Target |
Microsomal triglyceride transfer protein |
ANGPTL3 |
| Administration |
Daily oral dosing |
Monthly intravenous infusion |
| Key limitation |
Liver toxicity and gastrointestinal effects |
Infusion burden and biologic cost |
| Patient population |
Adults with HoFH |
Adults and adolescents aged 12 years and older with HoFH |
| Competitive advantage |
Oral administration and long clinical experience |
Strong efficacy in LDL-receptor-defective disease and pediatric labeling |
Lomitapide remains relevant for patients who prefer oral treatment, cannot access infusion services, or require another mechanism. Evinacumab is more competitive in patients with severe receptor-negative disease, treatment intolerance, or inadequate response to oral therapy.
What is the FDA regulatory status of Juxtapid?
The FDA approved Juxtapid under the orphan-drug framework with a REMS program because of the risk of hepatic toxicity.[2] The approval requires use with a low-fat diet and other lipid-lowering treatments. Juxtapid is not approved as a general cholesterol drug.
The regulatory profile includes:
- Prescription-only status.
- Adult HoFH indication in the original U.S. label.
- Restricted distribution through certified prescribers and pharmacies.
- Liver monitoring requirements.
- Contraindication in pregnancy because of potential fetal harm.
- Drug-interaction limitations involving CYP3A4 substrates and inhibitors.
The European Medicines Agency granted marketing authorization for Lojuxta for adults with HoFH as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available.[5]
When did lomitapide lose orphan exclusivity?
U.S. orphan-drug exclusivity generally lasted seven years from the FDA approval date. For Juxtapid, the relevant period began on Dec. 21, 2012 and ended in December 2019, subject to the specific scope of the orphan indication and any regulatory issues affecting the exclusivity record.[2]
Loss of orphan exclusivity did not automatically create immediate generic competition. Generic entry also depends on:
- Patent status.
- FDA approval of an abbreviated new drug application.
- Ability to satisfy bioequivalence requirements.
- Access to the reference product’s labeling and regulatory materials.
- Commercial attractiveness of a small HoFH market.
- REMS and distribution requirements.
- Manufacturing economics.
What patents protect lomitapide mesylate?
Lomitapide was developed from Bristol-Myers Squibb research on microsomal triglyceride transfer protein inhibitors. The original compound and related patent estate included composition-of-matter, pharmaceutical composition, and therapeutic-use claims.
The commercially relevant protection has historically included:
- Core small-molecule patents.
- Salt and crystalline-form protection.
- Formulation and capsule claims.
- Treatment claims directed to HoFH and LDL-C reduction.
- Manufacturing and process claims.
The practical strength of the estate has declined over time because the earliest compound patents and regulatory exclusivity periods have expired or approached expiration. Current protection depends more heavily on later-filed formulation, dosage, method-of-use, and process patents than on the original discovery claims.
The FDA Orange Book should be used to confirm active U.S. patents listed for the approved Juxtapid product and their use codes. Patent listings can change through expiration, delisting, litigation, or FDA administrative updates.[6]
Are there generic lomitapide products or Paragraph IV challenges?
The commercial threat from generic lomitapide has been limited by market size and development complexity. A Paragraph IV certification would require an ANDA applicant to assert that relevant listed patents are invalid, unenforceable, or not infringed. The applicant would then face potential Hatch-Waxman litigation and a possible 30-month stay of approval.
The principal generic-entry obstacles are:
- Small patient population.
- High need for specialist distribution.
- Potentially complex formulation and pharmacokinetic requirements.
- REMS and restricted-access logistics.
- Narrow reimbursement market.
- Limited opportunity to recover development and litigation costs.
A generic entrant could still target the market if it obtains a materially lower price and secures payer coverage. The most credible launch strategy would focus on a limited specialist channel rather than broad retail distribution.
What litigation and settlement agreements affect lomitapide?
Aegerion faced significant corporate, regulatory, and securities-related legal pressure during the period when Juxtapid was its main commercial asset. The U.S. Department of Justice announced a settlement with Aegerion in 2015 concerning allegations related to the marketing and promotion of Juxtapid, including off-label promotion and reimbursement practices. Aegerion agreed to pay approximately $40.1 million to resolve the matter.[7]
That settlement affected the product’s financial trajectory by increasing compliance costs, damaging commercial credibility, and reinforcing scrutiny of pricing and promotional practices.
No widely reported, market-defining generic patent settlement has established a clear early-entry date for lomitapide comparable to major mass-market drugs. Entry analysis therefore depends primarily on the current Orange Book record, any ANDA litigation, and the economic willingness of a generic sponsor to serve the HoFH market.
How strong is the lomitapide patent estate?
The estate is commercially durable but no longer structurally dominant. Its strengths are:
- Orphan-disease concentration.
- Specialist prescribing.
- Clinical familiarity since 2012.
- Regulatory barriers associated with liver monitoring.
- Product-specific distribution and reimbursement knowledge.
- High switching friction for patients responding to therapy.
Its weaknesses are:
- Expired U.S. orphan exclusivity.
- Aging composition-of-matter protection.
- A small potential customer base.
- Competition from a newer biologic.
- Clinical safety concerns.
- Limited ability to use broad patent claims against products with different mechanisms.
The most valuable remaining barriers are likely regulatory know-how, clinical positioning, payer relationships, and manufacturing consistency rather than broad exclusivity over the entire HoFH treatment market.
What are the likely generic launch scenarios?
Scenario 1: No near-term generic entry
This is commercially plausible if no applicant can justify the cost of formulation development, FDA review, and litigation for a small market. Chiesi would retain pricing power, subject to payer pressure and competitive substitution.
Scenario 2: One specialist generic entrant
A single approved generic could enter with a discount while preserving a meaningful branded market. The impact would depend on substitution rules and whether payers require switching.
Scenario 3: Multiple generic entrants
This would create rapid price erosion, but it is less likely than in a high-volume cardiovascular indication. Multiple entrants would require a market large enough to support several manufacturers despite low patient numbers.
Scenario 4: Therapeutic substitution
Evinacumab, LDL apheresis, or combination therapy could reduce lomitapide use without a generic launch. This is the principal competitive risk because it does not depend on patent expiration.
What is the revenue exposure for Chiesi?
Lomitapide is strategically useful but unlikely to be a primary revenue driver for Chiesi. The company’s portfolio includes larger or broader rare-disease and specialty products. Lomitapide contributes:
- A high-value specialist revenue stream.
- Access to HoFH treatment centers.
- Experience in ultra-rare cardiovascular disease.
- Potential combination use with other lipid-lowering therapies.
- Geographic expansion opportunities in markets with underdiagnosed HoFH.
Its downside exposure is concentrated. A loss of a few hundred treated patients can have a noticeable effect on product revenue, while overall Chiesi results are less sensitive because the company owns a diversified portfolio.
How does lomitapide compare with competing HoFH treatments?
Lomitapide is differentiated by oral administration and a mechanism that does not rely on LDL-receptor activity. Its disadvantages are liver monitoring, gastrointestinal tolerability, drug interactions, and a narrower adult label.
Evinacumab is differentiated by intravenous administration, a newer mechanism, and pediatric approval from age 12. LDL apheresis can produce substantial LDL-C reduction but is invasive, time-consuming, and dependent on specialized centers. PCSK9 inhibitors can be useful in some HoFH patients but generally have reduced efficacy where LDL-receptor function is severely impaired.
The treatment market is therefore segmented rather than winner-take-all. Patients may receive lomitapide, evinacumab, apheresis, or combinations based on genotype, LDL-C response, tolerability, payer policy, and treatment-center capacity.
Key Takeaways
- Lomitapide mesylate is a high-priced orphan therapy for HoFH, not a broad cholesterol drug.
- Juxtapid was FDA-approved in 2012; U.S. orphan exclusivity generally ended in December 2019.
- Chiesi acquired the product through its $1.25 billion acquisition of Amryt Pharma in 2023.
- Aegerion’s early revenue growth was followed by financial distress, compliance scrutiny, and corporate restructuring.
- Current product-level revenue is not publicly disclosed in the detail previously provided by Aegerion.
- Evinacumab is the principal branded competitor, while LDL apheresis remains an important non-drug alternative.
- Generic entry is possible after orphan-exclusivity expiry but is constrained by the small market, specialist distribution, regulatory controls, and manufacturing economics.
- The strongest remaining commercial barriers are patient identification, specialist access, safety monitoring, payer relationships, and clinical familiarity.
- Lomitapide is strategically valuable to Chiesi but is unlikely to be a portfolio-scale revenue driver.
FAQs
What is the annual cost of lomitapide mesylate treatment?
The annual cost varies by dose, payer, country, rebates, and patient-support programs. U.S. treatment has historically been priced in the high-cost orphan-drug range, with net cost below list price after discounts and assistance.
Is lomitapide safer than evinacumab?
The drugs have different risk profiles. Lomitapide has important hepatic and gastrointestinal risks, while evinacumab carries infusion-related and biologic-treatment risks. Treatment selection depends on patient characteristics and specialist assessment.
Can lomitapide be used with statins?
Yes. The FDA indication positions lomitapide as an adjunct to other lipid-lowering treatments, but dose limits and drug-interaction restrictions apply. The product label governs statin coadministration and monitoring.[2]
Does lomitapide work in LDL-receptor-negative HoFH?
Lomitapide can reduce lipoprotein production independently of normal LDL-receptor function, which is important in severe HoFH. Individual response varies, and treatment is generally combined with other lipid-lowering strategies.
Is lomitapide approved for children?
The original U.S. Juxtapid approval was for adults with HoFH. Evinacumab has a U.S. indication for patients aged 12 years and older, giving it a pediatric-label advantage in the HoFH market.[4]
References
-
Chiesi Farmaceutici. (2023). Chiesi completes acquisition of Amryt Pharma. Chiesi Group.
-
U.S. Food and Drug Administration. (2024). Juxtapid (lomitapide) prescribing information. FDA.
-
Familial Hypercholesterolemia Foundation. (2024). Homozygous familial hypercholesterolemia. FH Foundation.
-
U.S. Food and Drug Administration. (2021). FDA approves first treatment for patients with homozygous familial hypercholesterolemia aged 12 and older. FDA.
-
European Medicines Agency. (2024). Lojuxta: EPAR - product information. EMA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Department of Justice. (2015). Aegerion Pharmaceuticals agrees to pay $40.1 million to resolve allegations of off-label promotion and false claims. Department of Justice.
